반응식
[F:1][C:2]1[CH:3]=[C:4]([CH2:9][C:10]([NH:12][C@H:13]([C:15]([OH:17])=O)[CH3:14])=[O:11])[CH:5]=[C:6]([F:8])[CH:7]=1.Cl.Cl.[CH3:20][O:21][C:22](=[O:31])[C@H:23]([CH2:25][C:26]1[N:30]=[CH:29][NH:28][CH:27]=1)[NH2:24]>CO.C(Cl)Cl>[CH3:20][O:21][C:22](=[O:31])[C@H:23]([CH2:25][C:26]1[N:30]=[CH:29][NH:28][CH:27]=1)[NH:24][C:15](=[O:17])[C@H:13]([CH3:14])[NH:12][C:10](=[O:11])[CH2:9][C:4]1[CH:5]=[C:6]([F:8])[CH:7]=[C:2]([F:1])[CH:3]=1참가 물질
4
실험 절차
Following General Procedure A and using N-(3,5-difluorophenylacetyl)-L-alanine (from Example B2) and L-histidine methyl ester dihydrochloride (Sigma), the title compound was prepared as a solid (mp=195-197° C.). The reaction was monitored by tlc (Rf=0.29 in 10% CH3OH/CH2Cl2).
출처 및 근거
- ORD 기록
- ord-fde0312b335f4ca8ae2fe279155cb55f
- 출처 데이터셋
- uspto-grants-2001_02
- 특허 번호
- US06191166B1
연결된 노트
불러오는 중…